This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Mon, 06/03/2024 - 12:36 June 3, 2024 — HighLife SAS , a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today that the U.S. I am honored to lead the HighLife pivotal study.
milla1cf Wed, 05/08/2024 - 11:02 May 8, 2024 — 4C Medical Technologies, Inc. ("4C 4C Medical"), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has been granted Breakthrough Device designation by the U.S. If left untreated, MR can lead to heartfailure or death.
Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heartfailure patient on February 13, 2024 at Henry Ford Hospital in Detroit. Other symptoms include swelling in the abdomen, legs or neck veins.
Edwards Lifesciences is going all-in on structural heart and heartfailure, acquiring aortic valve-maker JenaValve Technology and implantable heartfailure monitor company Endotronix for $1.2B and up to $445M in milestone payments.
The device is being developed as a first-in-class implantable sensor to provide daily adjunctive objective cardiac parameter measurements enabling patients and clinicians to better manage their congestive heartfailure symptoms with current medication management tools. heartfailure market is projected to be $70B annually by 2030.
The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heartfailure.
The present invention relates to medical methods for transseptal access to the heart using steerable introducers based on the Company’s Morph DNA technology. This additional patent protection for BioCardia’s current and future products in this important existing market enhances shareholder value.
In the process, improving the ejection fraction and possibly reducing mitral regurgitation. We now have one more technology, on the verge of approval by the FDA. Final message WiSE CRT uses some revolutionary technology and it is a welcome addition in few eligible patients. CRT, cardiac resynchronization therapy. Reference 1.
Dr. Shreenivas brings his rich experience in both the clinical and commercial aspects of the structural heart landscape to his new role with Cardiac Dimensions. There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies. pivotal EMPOWER Trial,” said Dr. Shreenivas.
Image courtesy: Philips christine.book Wed, 06/12/2024 - 14:07 June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.
Although 5G technology is not available everywhere, lead-author Xianhong Shu, also of Zhongshan Hospital, said: “This system would increase the accessibility of better medical resources as patients may travel less to get diagnosis and medical advice from cardiologists based in referral centres.”
New York Valves marks the next iteration of this legacy, featuring three days of transformative research and techniques that will redefine the landscape of structural heart interventions. Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aortic stenosis.
New York Valves marks the next iteration of this legacy, featuring three days of transformative research and techniques that will redefine the landscape of structural heart interventions. Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aortic stenosis.
"Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,
MHIF was the top enroller (enrolling the first and largest number of patients) of all 68 clinical sites participating in the TRILUMINATE Pivotal trial in the United States, Canada and Europe, according to a statement issued by the Minneapolis Heart Institute Foundation on the research milestone.
After half a century of evidence suggesting the existence of mineralocorticoid receptors (MR) in the vasculature, the advent of technology to specifically knockout the MR from smooth muscle cells (SMCs) in mice has elucidated contributions of SMC-MR to cardiovascular function and disease, independent of the kidney.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content